OTCMKTS:PARNFParnell Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Parnell Pharmaceuticals Holdings Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.15 +0.01 (+7.14 %) (As of 08/10/2020 04:00 PM ET) Add Compare Share Today's Range$0.15Now: $0.15▼$0.2050-Day Range$0.05MA: $0.14▼$0.3052-Week Range$0.04Now: $0.15▼$0.36Volume12,600 shsAverage Volume7,507 shsMarket Capitalization$2.70 millionP/E RatioN/ADividend YieldN/ABeta2.41 ProfileAdvanced ChartCompetitorsEarningsInstitutional OwnershipHeadlinesShort InterestSocial Media Parnell Pharmaceuticals Holdings Ltd, a veterinary pharmaceutical company, focuses on developing, manufacturing, and commercializing various animal health solutions. The company operates through four segments: Companion Animal, Production Animal U.S., Production Animal Rest of World, and Contract Manufacturing. It markets various products, including estroPLAN and GONAbreed reproductive hormone products for breeding programs in dairy and beef cows; and Zydax for the treatment of osteoarthritis (OA) in dogs and horses; and Glyde, a nutraceutical product aids in the treatment of OA for dogs, as well as Reviderm, an anti-microbial liquid bandage for use in companion animals. The company is also developing various products, such as PAR121 for bone-related diseases and injuries in dogs, cats, and horses; and PAR122 for atopic dermatitis and other dermatological conditions, as well as PROCEPT, a next generation breeding program. Parnell Pharmaceuticals Holdings Ltd was incorporated in 2009 and is headquartered in Alexandria, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Parnell Pharmaceuticals. Previous Next 2.7 Community Rank Outperform VotesParnell Pharmaceuticals has received 109 “outperform” votes. (Add your “outperform” vote.)Underperform VotesParnell Pharmaceuticals has received 94 “underperform” votes. (Add your “underperform” vote.)Community SentimentParnell Pharmaceuticals has received 53.69% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Parnell Pharmaceuticals and other stocks. Vote “Outperform” if you believe PARNF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PARNF will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldParnell Pharmaceuticals does not currently pay a dividend.Dividend GrowthParnell Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Parnell Pharmaceuticals insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.54 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:PARNF Previous SymbolNASDAQ:PARN CUSIPN/A CIKN/A Webwww.parnell.com Phone61-2-9667-4411Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$14.67 million Price / Sales0.18 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares18,024,000Market Cap$2.70 million Next Earnings DateN/A OptionableNot Optionable $0.15 +0.01 (+7.14 %) (As of 08/10/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive PARNF News and Ratings via Email Sign-up to receive the latest news and ratings for PARNF and its competitors with MarketBeat's FREE daily newsletter. Parnell Pharmaceuticals (OTCMKTS:PARNF) Frequently Asked Questions How has Parnell Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Parnell Pharmaceuticals' stock was trading at $0.1001 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PARNF shares have increased by 49.9% and is now trading at $0.15. View which stocks have been most impacted by Coronavirus. Has Parnell Pharmaceuticals been receiving favorable news coverage? Headlines about PARNF stock have been trending somewhat negative on Monday, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Parnell Pharmaceuticals earned a daily sentiment score of -1.9 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news about Parnell Pharmaceuticals. Who are some of Parnell Pharmaceuticals' key competitors? Some companies that are related to Parnell Pharmaceuticals include Wellness Center USA (WCUI), Rexahn Pharmaceuticals (REXN), Amarillo Biosciences (AMAR), BENITEC BIOPHAR/S (BNTC), Medicure (MCUJF), X T L Biopharmaceuticals (XTLB), Xenetic Biosciences (XBIO), ANCHIANO THERAP/S (ANCN), Novus Therapeutics (NVUS), Reliv International (RELV), Nuvo Pharmaceuticals (NRIFF), OTCMKTS:EMBI (EMBI), Nemus Bioscience (NMUS), Auris Medical (EARS) and Acura Pharmaceuticals (ACUR). View all competitors. Who are Parnell Pharmaceuticals' key executives? Parnell Pharmaceuticals' management team includes the following people: Dr. Alan Richard Bell, Exec. Chairman (Age 63)Mr. Brad R. McCarthy, CEO, CFO, Chief Accounting Officer & Exec. Director (Age 43) What is Parnell Pharmaceuticals' stock symbol? Parnell Pharmaceuticals trades on the OTCMKTS under the ticker symbol "PARNF." How do I buy shares of Parnell Pharmaceuticals? Shares of PARNF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Parnell Pharmaceuticals' stock price today? One share of PARNF stock can currently be purchased for approximately $0.15. How big of a company is Parnell Pharmaceuticals? Parnell Pharmaceuticals has a market capitalization of $2.70 million and generates $14.67 million in revenue each year. What is Parnell Pharmaceuticals' official website? The official website for Parnell Pharmaceuticals is www.parnell.com. How can I contact Parnell Pharmaceuticals? Parnell Pharmaceuticals' mailing address is UNIT 4 CENTURY ESTATE 476 GARDENERS ROAD, ALEXANDRIA C3, 2015. The company can be reached via phone at 61-2-9667-4411 or via email at [email protected] This page was last updated on 8/10/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
